Last update June 2, 2022

Solriamfetol

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Solriamfetol is a central stimulant with actions similar to modafinil, although they are not structurally related. Selectively inhibits the reuptake of dopamine and norepinephrine. It is used in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Oral administration once daily.

Since the last update we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data do not allow to predict its possible excretion in breast milk. Its low protein binding and low molecular weight would favor it, but the high volume of distribution would prevent it.

The manufacturer (Jazz 2021, FDA 2019) and expert authors (LactMed) consider its administration possible during lactation, monitoring the infant for signs of irritability, insomnia, diarrhea, appetite and adequate weight gain.


See below the information of this related product:

  • Narcolepsy. Narkolepsy. (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

  • Armodafinil (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Methylphenidate ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Modafinil (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Sodium Oxybate (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Solriamfetol in other languages or writings:

Group

Solriamfetol belongs to this group or family:

Tradenames

Main tradenames from several countries containing Solriamfetol in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 95 %
Molecular weight 194 daltons
Protein Binding 13 -19 %
VD 2.8 l/Kg
pKa 15.68 -
Tmax 2 (1.2 - 3) hours
7.1 hours

References

  1. Jazz Ph. Solriamfetol (Sunosi). Drug Summary. 2021 Full text (in our servers)
  2. FDA. Solriamfetol (Sunosi). Drug Summary. 2019 Full text (in our servers)

Total visits

657

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM